Of the 24 drugs, three approvals deviated from the others -- aducanumab; the synthetic hormone hydroxyprogesterone caproate ...

The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...

As I ran from interview to interview across San Francisco, I was consistently warmed by the stories I was told by biotech and ...

The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...

Moderna provides updates on its business and pipeline progress at the J.P. Morgan Healthcare Conference.

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Study explains long-standing question of why Huntington’s disease symptoms typically do not appear until midlife even though ...

Failed to fetch dynamically imported module: https://ca.finance.yahoo.com/assets/_app/immutable/nodes/30.B7yWvFKE.js ...

In 2024, the Hatch-Waxman Act continued to play a critical role in the U.S. pharmaceutical landscape, driving the dynamics between ...

As the health care sector embraces AI, the incoming administration confronts some pressing challenges about what to regulate, ...

A new crop of companies is lining up to buy patient data from hospitals and sell it to those wanting to train AI or do ...

As the bull market enters its third year, the Sevens Report sees little reason for bearishness despite stretched valuations ...